Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.51 |
| ▸ | RAB9A | P51151 | 9/20 | 0.51 |
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.48 |
| ▸ | TP53 | P04637 | 6/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.48 |
| ▸ | RELA | Q04206 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24038648 | 0.86 | NPC1 (0.49) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL30517439 | 0.86 | NPC1 (0.49) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL30517481 | 0.81 | NPC1 (0.62) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL24039004 | 0.81 | NPC1 (0.62) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL30517467 | 0.81 | CYP1A2 (0.56) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL24038657 | 0.81 | CYP1A2 (0.56) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL24038659 | 0.78 | TP53 (0.54) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL30517434 | 0.78 | TP53 (0.54) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL24039002 | 0.77 | LMNA (0.56) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL24039054 | 0.77 | RXFP3 (0.54) | NPC1RAB9AMAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, IL1B, IL1RN | NPC1 3706/4885RAB9A 2738/4885MAPT 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.